|
| Entrez Id: |
4018 |
| Gene Symbol: |
LPA |
LPA
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Lipoprotein (a): its role in childhood thromboembolism.
|
9164807 |
1997 |
|
| Entrez Id: |
4018 |
| Gene Symbol: |
LPA |
LPA
|
0.500 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Lipoprotein (a): its role in childhood thromboembolism.
|
9164807 |
1997 |
|
| Entrez Id: |
2147 |
| Gene Symbol: |
F2 |
F2
|
0.420 |
Biomarker
|
phenotype |
LHGDN |
Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism.
|
14961151 |
2004 |
|
| Entrez Id: |
2147 |
| Gene Symbol: |
F2 |
F2
|
0.420 |
GeneticVariation
|
phenotype |
LHGDN |
Factor V Leiden and prothrombin gene 20210A variant in neonatal thromboembolism and in healthy neonates and adults: a study in a single center.
|
14578033 |
2003 |
|
| Entrez Id: |
2147 |
| Gene Symbol: |
F2 |
F2
|
0.420 |
Biomarker
|
phenotype |
CTD_human |
PT G20210A, factors V G1691A and 1299 His-Arg mutations and tamoxifen-associated thromboembolism in patients with breast cancer.
|
14693181 |
2003 |
|
| Entrez Id: |
2147 |
| Gene Symbol: |
F2 |
F2
|
0.420 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
| Entrez Id: |
3717 |
| Gene Symbol: |
JAK2 |
JAK2
|
0.410 |
Biomarker
|
phenotype |
CTD_human |
Essential thrombocythemia: past and present.
|
19636672 |
2009 |
|
| Entrez Id: |
3717 |
| Gene Symbol: |
JAK2 |
JAK2
|
0.410 |
GeneticVariation
|
phenotype |
LHGDN |
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
|
19174256 |
2009 |
|
| Entrez Id: |
3717 |
| Gene Symbol: |
JAK2 |
JAK2
|
0.410 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
| Entrez Id: |
5624 |
| Gene Symbol: |
PROC |
PROC
|
0.400 |
GeneticVariation
|
phenotype |
CLINVAR |
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.
|
31064749 |
2019 |
|
| Entrez Id: |
5624 |
| Gene Symbol: |
PROC |
PROC
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study.
|
8052960 |
1994 |
|
| Entrez Id: |
2153 |
| Gene Symbol: |
F5 |
F5
|
0.320 |
Biomarker
|
phenotype |
CTD_human |
We investigated whether FVL was associated with TE risk in women with early-stage breast cancer who took adjuvant tamoxifen.
|
20554945 |
2010 |
|
| Entrez Id: |
2153 |
| Gene Symbol: |
F5 |
F5
|
0.320 |
GeneticVariation
|
phenotype |
LHGDN |
Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation.
|
15912114 |
2005 |
|
| Entrez Id: |
2153 |
| Gene Symbol: |
F5 |
F5
|
0.320 |
Biomarker
|
phenotype |
CTD_human |
PT G20210A, factors V G1691A and 1299 His-Arg mutations and tamoxifen-associated thromboembolism in patients with breast cancer.
|
14693181 |
2003 |
|
| Entrez Id: |
2153 |
| Gene Symbol: |
F5 |
F5
|
0.320 |
GeneticVariation
|
phenotype |
LHGDN |
Factor V Leiden and prothrombin gene 20210A variant in neonatal thromboembolism and in healthy neonates and adults: a study in a single center.
|
14578033 |
2003 |
|
| Entrez Id: |
2155 |
| Gene Symbol: |
F7 |
F7
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage.
|
20172985 |
2010 |
|
| Entrez Id: |
10461 |
| Gene Symbol: |
MERTK |
MERTK
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation.
|
17047157 |
2007 |
|
| Entrez Id: |
2621 |
| Gene Symbol: |
GAS6 |
GAS6
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
The loss of any one of the Gas6-Rs protects mice against thromboembolism induced by collagen-epinephrine and stasis-induced thrombosis.
|
16564713 |
2006 |
|
| Entrez Id: |
2161 |
| Gene Symbol: |
F12 |
F12
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Defective thrombus formation in mice lacking coagulation factor XII.
|
16009717 |
2005 |
|
| Entrez Id: |
5627 |
| Gene Symbol: |
PROS1 |
PROS1
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
The incidence of thromboembolism was 2.5% per patient year for protein C deficient and 3.5% per patient year for protein S deficient patients.
|
8052960 |
1994 |
|
| Entrez Id: |
5327 |
| Gene Symbol: |
PLAT |
PLAT
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
[Dissolution of a right cardiac migrant thromboembolus in pulmonary embolism after treatment with rt-PA. Report of a successfully treated case].
|
8451030 |
1993 |
|
| Entrez Id: |
5328 |
| Gene Symbol: |
PLAU |
PLAU
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
Intra-arterial fibrinolytic therapy. Efficacy of streptokinase vs urokinase.
|
3718210 |
1986 |
|
| Entrez Id: |
2057 |
| Gene Symbol: |
EPOR |
EPOR
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
| Entrez Id: |
4524 |
| Gene Symbol: |
MTHFR |
MTHFR
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
| Entrez Id: |
9103 |
| Gene Symbol: |
FCGR2C |
FCGR2C
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|